Point of Care Diagnostics, per Industry report in the offer document of Molbio Diagnostics (commissioned by a company).
The global point-of-care testing (POCT) market is experiencing rapid expansion, driven by the increasing relevance of near-patient diagnostics, which offer faster turnaround times, lower capital costs, and ease of use in resource-limited or decentralized settings. Electrification and battery operation are crucial for penetration in emerging economies. Molecular diagnostics represents a highly competitive yet high-barrier space characterized by intensive R&D, stringent regulatory clearances (such as ICMR and WHO), and oligopolistic structures. Key growth areas include infectious disease screening (such as TB and COVID-19) and non-communicable diseases. Established players with strong technological IP, razor-and-blade recurring revenue profiles, and validated manufacturing capabilities are well-positioned to capitalize on this shift from centralized laboratory testing. [1]
| Figure | Period | Value |
|---|---|---|
| Market size [1] | equivalent to ₹ 2,588.6 billion | US$29.3 billion |
| Market CAGR [1] | 17.9% |
| Topic | Figure | Period | Value |
|---|---|---|---|
| Market size and growth | Market size [1] | equivalent to ₹ 2,588.6 billion | US$29.3 billion |
| Market size and growth | Market CAGR [1] | 17.9% |
According to an industry report in Molbio Diagnostics' offer document, the point of care diagnostics market was US$29.3 billion in equivalent to ₹ 2,588.6 billion.
An industry report in Molbio Diagnostics' offer document projects continued growth, a growth rate of 17.9% a year over . Forecasts are the source's, not FinMinutes'.
Built from 1 source: 1 company-commissioned report. Each figure carries its source number, which links to the full source list with dates and page references.
Figures are quoted from the sources listed above, with their dates and page references. They are not FinMinutes estimates and are not a recommendation about any security. All industries →